MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Danaher Corp

Slēgts

SektorsVeselības aprūpe

196.46 -0.12

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

192.46

Max

196.82

Galvenie mērījumi

By Trading Economics

Ienākumi

268M

1.1B

Pārdošana

738M

6.5B

P/E

Sektora vidējais

34.964

57.333

EPS

2.14

Dividenžu ienesīgums

0.69

Peļņas marža

16.611

Darbinieki

61,000

EBITDA

-230M

1.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+22.87% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.69%

2.63%

Nākamie ieņēmumi

2025. g. 22. jūl.

Nākamais dividenžu datums

2025. g. 25. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-29B

134B

Iepriekšējā atvēršanas cena

196.58

Iepriekšējā slēgšanas cena

196.46

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Danaher Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. apr. 10:34 UTC

Peļņas

Danaher 1Q Results Decline But Top Estimates

2025. g. 5. febr. 12:54 UTC

Peļņas

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

2025. g. 29. janv. 11:44 UTC

Peļņas

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

2024. g. 22. okt. 10:35 UTC

Peļņas

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

2025. g. 22. apr. 10:02 UTC

Peļņas

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

2025. g. 22. apr. 10:02 UTC

Peļņas

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

2025. g. 22. apr. 10:02 UTC

Peļņas

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

2025. g. 22. apr. 10:01 UTC

Peļņas

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

2025. g. 22. apr. 10:01 UTC

Peļņas

Danaher 1Q Adjusted Core Revenue Flat >DHR

2025. g. 22. apr. 10:00 UTC

Peļņas

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

2025. g. 22. apr. 10:00 UTC

Peļņas

Danaher 1Q Adj EPS $1.88 >DHR

2025. g. 22. apr. 10:00 UTC

Peļņas

Danaher 1Q EPS $1.32 >DHR

2025. g. 22. apr. 10:00 UTC

Peļņas

Danaher 1Q Sales $5.74B >DHR

2025. g. 22. apr. 10:00 UTC

Peļņas

Danaher 1Q Net $954M >DHR

2025. g. 29. janv. 15:25 UTC

Tirgus saruna
Peļņas

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

2025. g. 29. janv. 13:56 UTC

Top Ziņas
Peļņas

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

2025. g. 29. janv. 11:08 UTC

Peļņas

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

2025. g. 29. janv. 11:07 UTC

Peļņas

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

2025. g. 29. janv. 11:07 UTC

Peļņas

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

2025. g. 29. janv. 11:02 UTC

Peļņas

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

2025. g. 29. janv. 11:01 UTC

Peļņas

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

2025. g. 29. janv. 11:01 UTC

Peļņas

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Cont Ops EPS $1.49 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Net $1.09B >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q EPS $1.49 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Adj EPS $2.14 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Sales $6.5B >DHR

2024. g. 22. okt. 10:02 UTC

Peļņas

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

2024. g. 22. okt. 10:02 UTC

Peļņas

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Salīdzinājums

Cenas izmaiņa

Danaher Corp Prognoze

Cenas mērķis

By TipRanks

22.87% augšup

Prognoze 12 mēnešiem

Vidējais 241.2 USD  22.87%

Augstākais 265 USD

Zemākais 210 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Danaher Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

15

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

190.1 / 199.64Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.